ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Longboard Pharmaceuticals Inc

Longboard Pharmaceuticals Inc (LBPH)

36.78
0.83
(2.31%)
Closed July 22 4:00PM
38.02
1.24
(3.37%)
After Hours: 7:53PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
38.02
Bid
36.92
Ask
38.02
Volume
547,875
35.2606 Day's Range 37.185
3.60 52 Week Range 40.48
Market Cap
Previous Close
35.95
Open
36.10
Last Trade Time
Financial Volume
$ 19,967,372
VWAP
36.4451
Average Volume (3m)
456,644
Shares Outstanding
38,880,054
Dividend Yield
-
PE Ratio
-26.31
Earnings Per Share (EPS)
-1.4
Revenue
-
Net Profit
-54.42M

About Longboard Pharmaceuticals Inc

Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659. Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Longboard Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LBPH. The last closing price for Longboard Pharmaceuticals was $35.95. Over the last year, Longboard Pharmaceuticals shares have traded in a share price range of $ 3.60 to $ 40.48.

Longboard Pharmaceuticals currently has 38,880,054 shares outstanding. The market capitalization of Longboard Pharmaceuticals is $1.40 billion. Longboard Pharmaceuticals has a price to earnings ratio (PE ratio) of -26.31.

LBPH Latest News

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the...

Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies...

Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group...

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the...

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.691.8483793195837.3340.39535.260666848437.37562593CS
417.0781.479713603820.9540.4819.659782484532.50082109CS
1218.0190.004997501220.0140.4815.6445664427.20169847CS
2613.8657.367549668924.1640.4815.6452459423.31475257CS
5230.8426.5927977847.2240.483.654520622.8785534CS
15629.35338.5236447528.6740.482.720617620.82632661CS
26022.02137.6251640.482.719243020.45882072CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
158.14M
CMAXCareMax Inc
$ 5.19
(228.48%)
102.64M
NUKKNukkleus Inc
$ 0.499
(55.94%)
26.2M
SNOASonoma Pharmaceuticals Inc
$ 0.423
(37.34%)
4.88M
ONDSOndas Holdings Inc
$ 1.1297
(34.06%)
2.19M
CGBSCrown LNG Holdings Ltd
$ 0.9902
(-29.77%)
3.29M
LGCBLinkage Global Inc
$ 3.7833
(-27.45%)
166.7k
SPECSpectaire Holdings Inc
$ 0.395
(-24.76%)
1.78M
GSUNGolden Sun Health Technology Group Ltd
$ 5.07
(-24.55%)
155.37k
SLNASelina Hospitality PLC
$ 0.0364
(-23.04%)
75.77M
NVDANVIDIA Corporation
$ 123.45
(4.68%)
221.22M
SQQQProShares UltraPro Short QQQ
$ 8.08
(-4.49%)
176.65M
MIRAMIRA Pharmaceuticals Inc
$ 5.01
(627.35%)
151.42M
SERVServe Robotics Inc
$ 8.7192
(15.49%)
148.59M
NCPLNetcapital Inc
$ 0.1105
(6.25%)
121.97M

LBPH Discussion

View Posts
TechandBio TechandBio 2 weeks ago
MY best performing Bio this year! Surfs up Vertical debit spreads from $5.00 are up over 1430% wish i went heavier keep an eye on ICCM

$LBPH
πŸ‘οΈ0
da_stock_analyst da_stock_analyst 6 months ago
#LBPH 🔥 short squeeze might push this way higher! Nice set up!
πŸ‘οΈ0
Backstabbed Backstabbed 7 months ago
Insane … grats all
πŸ‘οΈ0
conix conix 7 months ago
LOTTO Ticket for 2024: Curative Biotechnology $CUBT @ $0.02 is a biotech with some very promising technology in the treatment of Age-Related Macular Degeneration (AMD). Metformin, a widely used diabetes drug, has been proven to have positive effects on patients with AMD. CUBT has a patented formulation for the direct delivery of metformin to the eye in the form of eye drops. The National Institutes of Health (NIH) will be funding a clinical trial on humans in 2024 in collaboration with the company. There has been a number of delays in the start of the trials, hence the low price, but the price has been firming up this past month. Although difficult to predict when these announcements happen, at these prices, CUBT is worth buying a small position (you can define "small") to make certain you are following the news and the price reaction so you can average up on your original position. Check the CUBT website out to see more info on the trials and the company's other drugs in the pipeline. Target Price by end of First Quarter (assuming clinical trial announcement)--$0.15).

SOURCE: https://www.reddit.com/r/pennystocks/comments/18uvm1j/trading_ideas_for_january_sing_migi_cubtmentioned/

It should go without saying, BUT some may need to read it...the above is someone's opinion. Nice to see anyways.
πŸ‘οΈ0
conix conix 7 months ago
Congrats on being a quick thinker. Per-market buying can be risky, but does pan out.
πŸ‘οΈ0
TheFinalCD TheFinalCD 7 months ago
The company has 9.5 months of cash left based on quarterly cash burn of -$13.28M and estimated current cash of $42.0M.
https://dilutiontracker.com/app/search/LBPH?a=dbb88c
πŸ‘οΈ0
Stockexpertpro Stockexpertpro 7 months ago
AVTX Data Due on Watch here after 1 for 240 RS micro Float
πŸ‘οΈ0
Laster Laster 7 months ago
Grabbed some at 8am immediately following news.
Looking good moving into open.
Sold half on double. Riding rest free.
What a way to start 2024!
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
tw0122 tw0122 7 months ago
An epileptic profit nice…
πŸ‘οΈ0
cityimport cityimport 7 months ago
My First Almost 200% Profit (Within One Hour) In 2024 ... :)))))))))))))

In @ 6.25
Out @ 17.95

LBPH
πŸ‘οΈ0